Creating new drugs to treat Alzheimer's disease
Development of soluble epoxide hydrolase inhibitors for the treatment of Alzheimer's disease
This study is looking at new ways to create medicines that can help treat Alzheimer's disease by making it easier for them to reach the brain, which could lead to better treatment options for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Michigan State University NIH-funded |
| Lab location | 1 site (East Lansing, United States) |
| Project ID | NIH-11023036 on NIH RePORTER |
What this research studies
This research focuses on developing new inhibitors for soluble epoxide hydrolase (sEH) to treat Alzheimer's disease, which currently has no effective cure. The team will explore how modifications to the chemical structure of these inhibitors can improve their ability to cross the blood-brain barrier, which is crucial for their effectiveness. By enhancing the properties of these compounds, the research aims to increase their potential to engage with the target in the brain and provide therapeutic benefits. Patients with Alzheimer's disease may benefit from these advancements if successful.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals aged 65 and older who are diagnosed with Alzheimer's disease.
Not a fit: Patients under the age of 65 or those without a diagnosis of Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve the quality of life for patients with Alzheimer's disease.
How similar studies have performed: While the approach of targeting soluble epoxide hydrolase is relatively novel, previous studies have shown promise in developing similar therapeutic strategies for neurological conditions.
Where this research is happening
East Lansing, United States
- Michigan State University — East Lansing, United States (Active)
Researchers
- Principal investigator: Lee, Kin Sing Stephen — Michigan State University
- Study coordinator: Lee, Kin Sing Stephen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.